Gritstone bio, Inc. (GRTS)
| Previous Close | 0.8061 |
| Open | 0.8200 |
| Bid | 0.7923 x 800 |
| Ask | 0.8062 x 1000 |
| Day's Range | 0.7800 - 0.8200 |
| 52 Week Range | 0.6700 - 3.3300 |
| Volume | |
| Avg. Volume | 2,805,474 |
| Market Cap | 84.949M |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2000 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.17 |
GlobeNewswireGritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
-- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the majority of participants studied, including those living with HIV, after administration of any of the samRNA constructs -- -- Comprehensive data set demonstrates a consistent and strong immunogenicity profile across multiple patient populations in South Africa, including people living with HIV -- EMERYVI
- GlobeNewswire
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The
- GlobeNewswire
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) -- -- Publication underscores the important role of antigen selection and cassette design in the development of neoan
